Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia - PubMed (original) (raw)
Clinical Trial
doi: 10.1081/PRG-120028286.
Affiliations
- PMID: 15117604
- DOI: 10.1081/PRG-120028286
Free article
Clinical Trial
Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia
Thomas Krauss et al. Hypertens Pregnancy. 2004.
Free article
Abstract
Objective: The aim of this study was to analyze if levels of plasma PlGF in the second half of pregnancy have predictive value for the identification of women destined to develop preeclampsia or another complication of pregnancy.
Material and methods: A bank of 1.543 randomly collected plasma samples (22-29 weeks of gestation) was established and PlGF concentrations were quantitated in a prospective longitudinal study in all pregnant women who developed a complication of pregnancy in late gestation (177 of 1.543) and the same number of gestational age matched pregnancies with normal outcome.
Results: Plasma PlGF levels in pregnant women rise steadily throughout pregnancy from the level of nonpregnant women (< 50 pg/mL) to levels exceeding 500 pg/mL after 30 weeks of gestation. Just 7.3% of pregnant women with normal outcome of pregnancy had PlGF levels of less than 200 pg/mL beyond 22 weeks of gestation (3.7% beyond 25 weeks of gestation). The rise in plasma PlGF in the second half of pregnancy was significantly attenuated in pregnancies that were complicated by preeclampsia in late gestation. Of all women who developed preeclampsia, 27.3% (12 of 44) had plasma PlGF levels below 200 pg/mL. The attenuation of the rise in plasma PlGF was not evident in other complications of pregnancy (transient hypertension, fetal retardation, pregnancy diabetes, premature contractions, proteinuria without hypertension, infections during pregnancy).
Conclusion: The rise in plasma PlGF levels observed in normal pregnancies is significantly attenuated in pregnancies complicated by preeclampsia. Yet, due to the low sensitivity and specificity, plasma PlGF levels in the second half of pregnancy have no predictive value for the identification of individual women destined to develop preeclampsia.
Similar articles
- Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?
Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Ghosh SK, et al. Arch Gynecol Obstet. 2013 May;287(5):865-73. doi: 10.1007/s00404-012-2662-2. Epub 2012 Dec 7. Arch Gynecol Obstet. 2013. PMID: 23224699 - Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies.
Bersinger NA, Ødegård RA. Bersinger NA, et al. Acta Obstet Gynecol Scand. 2004 Jan;83(1):37-45. Acta Obstet Gynecol Scand. 2004. PMID: 14678084 - Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M. Wikström AK, et al. Obstet Gynecol. 2007 Jun;109(6):1368-74. doi: 10.1097/01.AOG.0000264552.85436.a1. Obstet Gynecol. 2007. PMID: 17540809 - Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes.
Sherrell H, Dunn L, Clifton V, Kumar S. Sherrell H, et al. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:26-34. doi: 10.1016/j.ejogrb.2018.03.059. Epub 2018 Mar 30. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29631209 Review. - Blood laboratory testing for early prediction of preeclampsia: chasing the finish line or at the starting blocks?
Montagnana M, Danese E, Lippi G, Fava C. Montagnana M, et al. Ann Med. 2017 May;49(3):240-253. doi: 10.1080/07853890.2016.1255350. Epub 2016 Nov 29. Ann Med. 2017. PMID: 27791388 Review.
Cited by
- Maternal Smoking History Enhances the Expression of Placental Growth Factor in Invasive Trophoblasts at Early Gestation Despite Cessation of Smoking.
Kawashima A, Koide K, Hasegawa J, Arakaki T, Takenaka S, Maruyama D, Matsuoka R, Sekizawa A. Kawashima A, et al. PLoS One. 2015 Jul 27;10(7):e0134181. doi: 10.1371/journal.pone.0134181. eCollection 2015. PLoS One. 2015. PMID: 26214510 Free PMC article. Clinical Trial. - Preeclampsia: increased expression of soluble ADAM 12.
Gack S, Marmé A, Marmé F, Wrobel G, Vonderstrass B, Bastert G, Lichter P, Angel P, Schorpp-Kistner M. Gack S, et al. J Mol Med (Berl). 2005 Nov;83(11):887-96. doi: 10.1007/s00109-005-0714-9. Epub 2005 Oct 25. J Mol Med (Berl). 2005. PMID: 16247621 - The Impact of PTPRK and ROS1 Polymorphisms on the Preeclampsia Risk in Han Chinese Women.
Li H, Yan X, Yang M, Liu M, Tian S, Yu M, Li WP, Zhang C. Li H, et al. Int J Hypertens. 2021 Oct 4;2021:3275081. doi: 10.1155/2021/3275081. eCollection 2021. Int J Hypertens. 2021. PMID: 34646579 Free PMC article. - Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
Ren Z, Cui N, Zhu M, Khalil RA. Ren Z, et al. Am J Physiol Heart Circ Physiol. 2018 Jul 1;315(1):H33-H47. doi: 10.1152/ajpheart.00045.2018. Epub 2018 Mar 23. Am J Physiol Heart Circ Physiol. 2018. PMID: 29569955 Free PMC article. - First-trimester maternal serum PP13 in the risk assessment for preeclampsia.
Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, Edwin S, Chefetz I, Gomez R, Nien JK, Sammar M, Pineles B, Hassan SS, Meiri H, Tal Y, Kuhnreich I, Papp Z, Cuckle HS. Romero R, et al. Am J Obstet Gynecol. 2008 Aug;199(2):122.e1-122.e11. doi: 10.1016/j.ajog.2008.01.013. Epub 2008 Jun 9. Am J Obstet Gynecol. 2008. PMID: 18539259 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources